Scholarlink

Purpose of Review <p>This review synthesizes evidence on NUF2 in digestive system cancers, delineates its oncogenic mechanisms, and evaluates its potential as a diagnostic and therapeutic target, addressing unmet needs for these high-incidence, poor-prognosis malignancies.</p> Recent Findings <p>NUF2, a key cell cycle protein, is significantly overexpressed in digestive system cancers. Mechanistic studies reveal that it promotes tumorigenesis by driving genomic instability, inhibiting apoptosis, inducing epithelial–mesenchymal transition, and remodeling the tumor immune microenvironment. Emerging therapeutic strategies–including natural compounds (e.g., berberine, fisetin) and peptide-based vaccines–shows preclinical efficacy in targeting NUF2.</p> Summary <p>NUF2 represents a promising biomarker and therapeutic target for digestive system cancers. While preclinical evidence is compelling, clinical translation remains at an early stage. Future efforts should focus on large-scale clinical validation, optimizing targeted interventions, and developing combinatorial approaches to improve patient outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Research Report on NUF2-Targeted Therapy for Digestive System Cancers: from Mechanism to Clinical Translation

  • 期刊论文

  • 发表日期：

    2026年2月7日

查看全文
  • Luxi Yang,
  • Zhonghong Xiong,
  • Jing Yang,
  • Jingsong Mei,
  • Jinsen Wei,
  • Yali Liu,
  • Yumin Li

摘要

Purpose of Review

This review synthesizes evidence on NUF2 in digestive system cancers, delineates its oncogenic mechanisms, and evaluates its potential as a diagnostic and therapeutic target, addressing unmet needs for these high-incidence, poor-prognosis malignancies.

Recent Findings

NUF2, a key cell cycle protein, is significantly overexpressed in digestive system cancers. Mechanistic studies reveal that it promotes tumorigenesis by driving genomic instability, inhibiting apoptosis, inducing epithelial–mesenchymal transition, and remodeling the tumor immune microenvironment. Emerging therapeutic strategies–including natural compounds (e.g., berberine, fisetin) and peptide-based vaccines–shows preclinical efficacy in targeting NUF2.

Summary

NUF2 represents a promising biomarker and therapeutic target for digestive system cancers. While preclinical evidence is compelling, clinical translation remains at an early stage. Future efforts should focus on large-scale clinical validation, optimizing targeted interventions, and developing combinatorial approaches to improve patient outcomes.